Adma Biologics reported $20.68M in Sales Revenues for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Adma Biologics ADMA:US $ 20.68M 2.85M
Agile Therapeutics AGRX:US 1.29M 102K
Alnylam Pharmaceuticals ALNY:US $ 187.63M 32.92M
Biocryst Pharmaceuticals BCRX:US $ 40.99M 8.96M
China Cord Blood CO:US 313.67M 1.5M
Dynavax Technologies DVAX:US $ 108.27M 55.5M
Kindred Biosciences KIN:US $ 3.54M 1.14M
Minerva Neurosciences NERV:US $ 0 0
Novavax NVAX:US $ 178.84M 119.17M
Omeros OMER:US $ 30M 1.18M
Takeda 4502:JP Y 844820M 104783M